In the race to end the HIV epidemic, Gilead Sciences is at the forefront, offering innovative solutions and support to bridge existing gaps in prevention and treatment. With a focus on historically underserved communities, Gilead’s efforts aim to overcome stigma and improve access to HIV prevention strategies, such as pre-exposure prophylaxis (PrEP). This article explores how Gilead is transforming the landscape of HIV prevention and its impact on communities most in need.
Empowering Through Innovation
Pre-exposure prophylaxis (PrEP) has revolutionized the fight against HIV/AIDS. When taken as prescribed, this daily oral medication can reduce the risk of acquiring HIV from sex by about 99%. Despite its effectiveness, PrEP is not universally adopted. As Dázon Dixon Diallo, founder and president of SisterLove, an Atlanta-based women’s HIV advocacy organization, notes, “The idea of taking medication when one isn’t sick or doesn’t have a diagnosis is stigmatizing for anyone because that’s not considered the norm.”
The stigma surrounding HIV prevention extends to perceptions about taking medication when one is healthy. Diallo emphasizes that for many, including those not fully informed, taking HIV prevention medication is misunderstood. Gilead aims to bridge this gap by introducing long-acting HIV prevention options, which could enhance adherence by reducing the frequency of dosing and mitigating stigma.
Addressing Disparities in Access
Although PrEP is a powerful tool, its adoption is uneven across different demographics. According to the CDC, while 94% of white men who could benefit from PrEP are prescribed it, only 14% of Black men receive the same prescription. This disparity is alarming, particularly as Black Americans continue to experience the highest rates of new HIV diagnoses. The Southern United States, home to nearly 60% of America’s Black population, also faces disproportionate rates of HIV-related deaths and diagnoses.
Deborah Wafer, executive director of public affairs in U.S. virology at Gilead Sciences, highlights stigma as a significant barrier. “I’m a nurse practitioner by training,” Wafer says, “and the women I’ve taken care of who are living with HIV say they have to deal with HIV stigma regularly.”
Innovative Solutions and Community Support
To tackle these challenges, Gilead has introduced a long-acting injectable for HIV prevention, approved by the FDA in mid-June. This innovation could be transformative for individuals who struggle with daily medication regimens, particularly within Black communities. The injectable reframes HIV prevention, making it more accessible and less stigmatized.
Culturally competent education is equally vital. Effective communication requires understanding and meeting communities where they are. For example, reaching Black women involves engaging with them in settings such as hair salons and churches, and conveying why HIV prevention matters to them personally.
Supporting Grassroots Initiatives
Gilead is actively involved in educational initiatives like Risky Dinner Conversations, where influential Black women discuss the stigmas impacting HIV disparities. These efforts have garnered significant social media engagement and community involvement, underlining the importance of tailored messaging.
Since 2010, Gilead has provided nearly $35.8 million to support Black women-led or serving organizations, with $28 million directed toward ending the HIV epidemic. SisterLove, a beneficiary of Gilead’s grants, has expanded its community services, creating mobile clinics to reach underserved populations.
Other grant recipients, such as Baltimore Safe Haven and Waco Theater Center, use innovative approaches to combat HIV stigma and provide life-saving resources. Wafer acknowledges, “We know that medicines alone won’t stop this epidemic, which is why Gilead is partnering with so many talented and dedicated individuals.”
Gilead Sciences remains committed to equipping all communities, particularly Black women, with the resources needed to confront the HIV epidemic, signaling a hopeful direction for future prevention and treatment efforts.
